Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences is seeing strong potential in its drug candidate VTAMA (tapinarof), which is in its commercial stage and is expected to differentiate itself from competitors due to its once-per-day dosing and favorable tolerability. With other drug candidates in different stages of development and a strong Phase Ib hemodynamic profile for mosliciguat, Roivant shows a promising outlook for future revenue growth. The company reported total revenue of $2.5M in 4Q26 and has a strong cash runway of $4.3B expected to carry it into profitability. However, risks to consider for the company include regulatory and clinical uncertainties as well as potential competition in the biopharmaceutical market.

Bears say

Roivant Sciences is likely to struggle in the future due to a lack of major developments and progress in its current drug candidates, with its flagship drug VTAMA (tapinarof) being the only one in its commercial stage. There is also increasing competition in the biopharmaceutical industry, with other companies developing similar treatments. Additionally, Roivant's financials may be hindered by the significant amount of capital needed for clinical trials and drug development.

ROIV has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 10 analysts, ROIV has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.